

**GUIDANCE FOR INDUSTRY
CONSULTATION**

GN-14: Guidance on the Risk Classification of
In Vitro Diagnostic Medical Devices

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

CONTENTS

1. INTRODUCTION..... 4

 1.1. Purpose 4

 1.2. Background..... 4

 1.3. Scope 4

 1.4. Definitions..... 5

2. GENERAL PRINCIPLES..... 9

3. CLASSIFICATION SYSTEM FOR IVD MEDICAL DEVICES..... 10

4. THE DETERMINATION OF DEVICE RISK CLASS BY THE PRODUCT OWNER USING THE RULES-BASED SYSTEM..... 10

5. CLASSIFICATION RULES..... 12

APPENDIX A 18

27 **REVISION HISTORY**

28

<u>Guidance Version (Effective Date) [3 Latest Revisions]</u>	<u>Revision</u>
GN-14: Revision 1 (October 2008)	R1
R1.1 ► GN-14: Revision 1.1 (May 2014)	R1.1
R1.2 ► GN-14: Revision 1.2 (01 December 2017)	R1.2
R2 ► GN-14: Revision 2 (01 June 2018)	R2
R3 ► GN-14: Revision 3 (Xx June 2023)	R3

**Where applicable, changes and updates made in each document revision are annotated with or within the arrow symbol "►". Deletions may not be shown*

29

30

31

32

33 1. INTRODUCTION

34 1.1. Purpose

35 This document provides guidance to assist product owners in risk classification
36 of *in vitro* diagnostic (IVD) medical devices using the appropriate risk
37 classification rules.

38

39

40 1.2. Background

41 Regulatory controls should be proportional to the level of risk associated with
42 an *in vitro* diagnostic (IVD) medical device. The level of regulatory control
43 should increase with increasing degree of risk, taking account of the benefits
44 offered by use of the IVD medical device. Therefore, there is a need to classify
45 IVD medical devices based on their risks to patients, users and other persons.

46

47 The risk presented by a particular IVD medical device depends substantially on
48 its intended purpose and the effectiveness of the risk management techniques
49 applied during design, manufacture and use.

50

51 The risk presented by an IVD medical device also depends, in part, on its
52 intended user(s), its mode of operation, and/or technologies.

53

54

55 1.3. Scope

56 This document is applicable to IVD device products that fall within the definition
57 of an IVD medical device as defined in First Schedule of the Health Products
58 Act (*Act*).

59

60

61

62

63 1.4. Definitions

64 Definitions that do not indicate they are set out in the *Act* and Health Products
65 (Medical Devices) Regulations 2010 (*Regulations*) are intended as guidance in
66 this document. These definitions are not taken verbatim from the above
67 legislation and should not be used in any legal context. These definitions are
68 meant to provide guidance in layman terms.

69
70 **ACCESSORY:** for the purposes of this guidance document, means an article
71 that is intended specifically by its product owner to be used together with a
72 particular medical device to enable or assist that device to be used in
73 accordance with its intended purpose. An accessory is typically intended to be
74 used for one or more of the purposes as described in the definition of medical
75 device and therefore should be considered a medical device.

76
77 **EXAMINATION:** means a set of operations having the object of determining the
78 value of a property.

79 *NOTE Examination of an analyte in a biological sample is commonly referred to as a*
80 *test, assay or analysis.*

81
82 **R2 ►**

83 **HARM (as set out in the Regulations):** means any physical injury or damage to
84 the health of a person, or any damage to property or the environment. ◀

85
86 **HAZARD (as set out in the Regulations):** means any potential source of harm.

87
88 **INSTRUMENT:** Equipment or apparatus intended by the product owner to be
89 used as IVD medical device.

90
91 **INTENDED PURPOSE/INTENDED USE (as set out in the Regulations):** in
92 relation to a medical device or its process or service, means the objective
93 intended use or purpose, as reflected in the specifications, instructions and
94 information provided by the product owner of the medical device.

95

96 **IN VITRO DIAGNOSTIC (IVD) PRODUCT** (as set out in the Regulations):

97 means any reagent, reagent product, calibrator, control material, kit, instrument,
98 apparatus, equipment or system, whether used alone or in combination with
99 any other reagent, reagent product, calibrator, control material, kit, instrument,
100 apparatus, equipment or system, that is intended by its product owner to be
101 used in vitro for the examination of any specimen, including any blood or tissue
102 donation, derived from the human body, solely or principally for the purpose of
103 providing information —

- 104 • concerning a physiological or pathological state or a congenital
105 abnormality;
- 106 • to determine the safety and compatibility of any blood or tissue donation
107 with a potential recipient thereof; or
- 108 • to monitor therapeutic measures; and

109 includes a specimen receptacle;

110

111 **IVD MEDICAL DEVICE FOR SELF-TESTING:** Any IVD medical device
112 intended by the product owner for use by lay persons.

113

114 **LAY PERSON:** Any individual who does not have formal training in a relevant
115 field or discipline.

116

117 **NEAR PATIENT TESTING:** Any testing performed outside a laboratory
118 environment by a healthcare professional not necessarily a laboratory
119 professional, generally near to, or at the side of, the patient. Also known as
120 Point-of-Care (POC).

121

122 **PRODUCT OWNER** (as set out in the Regulations): in relation to a health
123 product, means a person who —

- 124 • supplies the health product under his own name, or under any trade mark,
125 design, trade name or other name or mark owned or controlled by him; and

126 • is responsible for designing, manufacturing, assembling, processing,
127 labelling, packaging, refurbishing or modifying the health product, or for
128 assigning to it a purpose, whether those tasks are performed by him or on
129 his behalf.

130

131 **REAGENT**: Any chemical, biological or immunological components, solutions
132 or preparations intended by the product owner to be used as IVD medical
133 devices.

134

135 **RISK (as set out in the Regulations)**: means a combination of the probability of
136 occurrence of harm and the severity of that harm.

137

138 **SELF-TESTING**: Testing performed by lay persons.

139

140 **R2** ►

141 **SPECIMEN (as set out in the Regulations)**: means a discrete portion of a body
142 fluid or tissue, or of any other sample associated with a human body, which is
143 taken for —

144 (a) examination;

145 (b) study; or

146 (c) analysis of one or more quantities or characteristics, in order to determine
147 the character of the whole ◀

148

149 **SPECIMEN RECEPTACLE (as set out in the Regulations)**: An IVD medical
150 device, whether vacuum-type or not, specifically intended by their product
151 owner for the primary containment of specimens derived from the human body.

152

153 **R3** ►

154 **STANDALONE SOFTWARE (also known as SaMD in IMDRF technical**
155 **documents)** : A software and/or mobile application that is intended to function
156 by itself and are not intended for use to control or affect the operation of other
157 hardware medical devices. ◀

158

159 **TRANSMISSIBLE AGENT:** An agent capable of being transmitted to a person,
160 as a communicable, infectious or contagious disease.

161

162 **TRANSMISSION:** The conveyance of disease to a person.

163

GUIDANCE FOR INDUSTRY CONSULTATION

164 **2. GENERAL PRINCIPLES**

165 The classification for an IVD medical device is determined based on a set of
166 rules derived from those features that create risk. These include:

- 167 • the intended purpose and indications for use as specified by the product
168 owner (including but not limited to specific disorder, populations, condition
169 or risk factor for which the test is intended),
- 170 • the technical/scientific/medical expertise of the intended user (lay person or
171 healthcare professional),
- 172 • the importance of the information to the diagnosis (sole determinant or one
173 of several), taking into consideration the natural history of the disease or
174 disorder including presenting signs and symptoms which may guide a
175 physician,
- 176 • the impact of the result (true or false) to the individual and/or to public health.

177

178 *NOTE* *Regardless of the risk class, all medical devices including IVD medical devices*
179 *must meet the Essential Principles of Safety and Performance of Medical Devices and labelling*
180 *requirements.*

181

182

183

184

185

186

187

188

189

190

191

192 3. CLASSIFICATION SYSTEM FOR IVD MEDICAL DEVICES

193 IVD medical devices are classified into four classes, based on the individual
194 risk and public health risk level.

195

196 Table 1: Classification system for IVD Medical Devices

CLASS	RISK LEVEL	DEVICE EXAMPLES
A	Low Individual Risk and Low Public Health Risk	Specimen receptacle
B	Moderate Individual Risk and/or Low Public Health Risk	Vitamin B12, Pregnancy self testing, Anti-Nuclear Antibody, Urine test strips
C	High Individual Risk and/or Moderate Public Health Risk	Blood glucose self testing, HLA typing, PSA screening, Rubella IgM
D	High Individual Risk and High Public Health Risk	HIV blood donor screening, HIV diagnostic kit

198

199 Table 1 indicates the four risk classes for IVD medical devices. The examples
200 given are for illustration only and the product owner must apply the classification
201 rules to each IVD medical device according to its intended purpose.

202

203

204 4. THE DETERMINATION OF DEVICE RISK CLASS BY THE PRODUCT 205 OWNER USING THE RULES-BASED SYSTEM

206 The product owner should:

- 207 • decide if the product concerned is an IVD medical device based on the
208 intended purpose and the indications for use using the definition of IVD;
- 209 • take into consideration all the rules in order to establish the proper
210 classification for the device. Apply the classification rules to each IVD
211 medical device according to its intended purpose. Where an IVD medical
212 device has multiple intended purposes as specified by the product owner,
213 which places the device into more than one class, it should be classified to
214 the higher class;

- 215 • where more than one of the classification rules applies to the IVD medical
216 device, it should be assigned the highest risk class;
- 217 • the justification for placing a product into a particular risk class should be
218 documented.

219

220 Other factors influencing device classification include:

- 221 • calibrators intended to be used with an IVD reagent should be treated in the
222 same class as the IVD reagent;
- 223 • R3 ► control materials with quantitative or qualitative assigned values
224 intended for one specific analyte or multiple analyte should be placed in the
225 same class as the IVD reagent(s);
- 226 • Most software is incorporated into the IVD medical device itself, for example,
227 embedded software to operate an analyser. For such software, where it
228 controls or influences the intended output of an IVD medical device, it will
229 have the same class as the IVD medical device itself.
- 230 • There is some software that is not incorporated (embedded) into the medical
231 device itself, such as software to provide an analysis based on the results
232 from the analyser. Such software is deemed to be standalone software.
233 When it is not incorporated in an IVD medical device, it is classified in its
234 own right using the classification rules in this document.

235 ◀

236

237

238

239

240

241 5. CLASSIFICATION RULES

242 **RULE 1:** IVD medical devices intended for the following purposes are
243 classified as Class D:

- 244 a) devices intended to be used to detect the presence of, or exposure to, a
245 transmissible agent in blood, blood components, blood derivatives, cells,
246 tissues or organs **R3** ▶ or any of their derivatives in order to assess
247 their suitability for transfusion or transplantation, or cell administration.
- 248 b) devices intended to be used to detect the presence of, or exposure to, a
249 transmissible agent that causes a life-threatening, often incurable,
250 disease with a high or suspected high risk of propagation. ◀

251

252 **Rationale:** The application of this rule as defined above should be in
253 accordance with the rationale that follows: IVD medical devices in this Class
254 are intended to be used to ensure the safety of blood and blood components
255 for transfusion and/or cells, tissues and organs for transplantation. In most
256 cases, the result of the test is the major determinant as to whether the
257 donation/product will be used. Serious diseases are those that result in death
258 or long-term disability, which are often incurable or require major therapeutic
259 interventions and where an accurate diagnosis is vital to mitigate the public
260 health impact of the condition.

261

262 **Examples:** Tests to detect infection by HIV, HCV, HBV, HTLV. This Rule
263 applies to first-line assays, confirmatory assays and supplemental assays.

264

265

266 **RULE 2:** IVD medical devices intended to be used for blood grouping, or
267 tissue typing to ensure the immunological compatibility of blood, blood
268 components, cells, tissue or organs that are intended for transfusion or
269 transplantation, **R3** ▶ or cell administration, are classified as Class C, except
270 when intended to determine the presence of the antigen or antibody for any of
271 the following markers ◀:

272 ABO system [A (ABO1), B (ABO2), AB (ABO3)], rhesus system [RH1 (D), RH2
273 (C), RH3 (E), RH4 (c), RH5 (e)], Kell system [Kel1 (K)], Kidd system [JK1 (Jka),
274 JK2 (Jkb)] and Duffy system [FY1 (Fya), FY2 (Fyb)] determination which are
275 classified as Class D.

276

277 **Rationale:** The application of this rule as defined above should be in
278 accordance with the following rationale: A high individual risk, where an
279 erroneous result would put the patient in an imminent life-threatening situation
280 places the device into Class D. The rule divides blood-grouping IVD medical
281 devices into two subsets, Class C or D, depending on the nature of the blood
282 group antigen / antibody that the IVD medical device is designed to detect, and
283 its importance in a transfusion setting.

284

285 **Examples:** HLA, Duffy system (other Duffy systems except those listed in the
286 rule as Class D are in Class C).

287

288

289 **R3** ►

290 **RULE 3:** IVD medical devices are classified as Class C if they are intended
291 for use:

292 a) in detecting the presence of, or exposure to, a sexually transmitted agent
293 (e.g. Sexually transmitted diseases, such as *Chlamydia trachomatis*,
294 *Neisseria gonorrhoeae*).

295 b) in detecting the presence in cerebrospinal fluid or blood of an infectious
296 agent with a risk of limited propagation (e.g. *Neisseria meningitidis* or
297 *Cryptococcus neoformans*).

298 c) in detecting the presence of an infectious agent where there is a significant
299 risk that an erroneous result would cause death or severe disability to the
300 individual, fetus, or embryo being tested or to the individual's offspring
301 (e.g. diagnostic assay for CMV, *Chlamydia pneumoniae*, Methycillin
302 Resistant *Staphylococcus aureus*).

- 303 d) in pre-natal screening of women in order to determine their immune status
304 towards transmissible agents (e.g. Immune status tests for Rubella or
305 Toxoplasmosis).
- 306 e) in determining infective disease status or immune status, and where there
307 is a risk that an erroneous result will lead to a patient management
308 decision resulting in an imminent life-threatening situation or severe
309 disability for the patient or for the patient's offspring (e.g. Enteroviruses,
310 CMV and HSV in transplant patients).
- 311 f) in screening for selection of patients for selective therapy and
312 management, or in the diagnosis of cancer (e.g. personalised medicine).
- 313 g) to be used for disease staging, where there is a risk that an erroneous
314 result would lead to a patient management decision resulting in a life-
315 threatening situation for the patient or for the patient's offspring (e.g. Brain
316 type natriuretic peptide).
- 317 h) in human genetic testing (e.g. Huntington's Disease, Cystic Fibrosis).
- 318 i) to monitor levels of medicines, substances or biological components,
319 when there is a risk that an erroneous result will lead to a patient
320 management decision resulting in an immediate life-threatening situation
321 for the patient or for the patient's offspring (e.g. Cardiac markers,
322 cyclosporin, prothrombin time testing).
- 323 j) in the management of patients suffering from a life-threatening disease or
324 condition (e.g. HCV viral load, HIV Viral Load and HIV and HCV geno-
325 and subtyping).
- 326 k) in screening for congenital disorders in the fetus or embryo (e.g. Spina
327 Bifida or Down Syndrome).
- 328 l) in screening for congenital disorders in new-born babies where failure to
329 detect and treat such disorders could lead to life-threatening situations or
330 severe disabilities (e.g. G6PD). ◀

331

332 **Rationale:** The application of this rule as defined above should be in
333 accordance with the rationale for this rule which is as follows: IVD medical
334 devices in this Class present a moderate public health risk, or a high individual

335 risk, where an erroneous result would put the patient in an imminent life-
336 threatening situation, or would have a major negative impact on outcome. The
337 IVD medical devices provide the critical, or sole, determinant for the correct
338 diagnosis. They may also present a high individual risk because of the stress
339 and anxiety resulting from the information and the nature of the possible follow-
340 up measures.

341

342

343 R3 ►

344 **RULE 4:** IVD medical devices intended for self-testing or near-patient
345 testing are classified as Class C, except those devices from which the result is
346 not determining a medically critical status, or is preliminary and requires follow-
347 up with the appropriate laboratory test in which case they are Class B.

348

349 **Rationale:** The application of this rule as defined above should be in
350 accordance with the rationale for this rule which is as follows: In general, these
351 IVD medical devices are used by individuals with no technical expertise and
352 thus the labelling and instructions for use are critical to the proper outcome of
353 the test.

354

355 **Examples for Self-testing / near patient testing Class C:** Blood glucose
356 monitoring, blood gases.

357 **Examples for Self-testing Class B:** Pregnancy self test, Fertility testing, Urine
358 test strip. ◀

359

360

361 R3 ►

362 **RULE 5:** The following IVD medical devices are classified as Class A:

363 a) products for general use in clinical laboratory, or accessories which
364 possess no critical characteristics, intended by the product owner to make
365 them suitable for in vitro diagnostic procedures related to a specific

366 examination (e.g. buffer solutions, washing solutions, general culture
367 media and histological stains).

368 b) standalone instruments (inclusive of software) intended by the product
369 owner specifically to be used for in vitro diagnostic procedures, not
370 intended for use in specific medical diagnostic purposes.

371 c) specimen receptacles (e.g. plain urine cup). ◀

372

373 *NOTE Any product for general laboratory use not manufactured, sold or represented*
374 *for use in specified in vitro diagnostic applications are not deemed to be IVD medical devices.*

375 **R2** ▶ *These include reagents, instruments, apparatus, equipment or systems that are intended*
376 *for general laboratory applications and not intended by the product owner as medical devices.*

377 *An example of general laboratory equipment would be an incubator.* ▶

378

379 **Rationale:** The application of this rule as defined above should be in
380 accordance with the rationale for this rule which is as follows: These IVD
381 medical devices present a low individual risk and no or minimal public health
382 risk.

383

384

385 **RULE 6:** IVD medical devices not covered in Rules 1 through 5 are
386 classified as Class B.

387

388 **Rationale:** The application of this rule as defined above should be in
389 accordance with the rationale for this rule which is as follows: These IVD
390 medical devices present a moderate individual risk as they are not likely to lead
391 to an erroneous result that would cause death or severe disability, have a major
392 negative impact on patient outcome or put the individual in immediate danger.

393 The IVD medical devices give results that are usually one of several
394 determinants. If the test result is the sole determinant however other information
395 is available, such as presenting signs and symptoms or other clinical
396 information that may guide a physician, such that classification into Class B
397 may be justified. Other appropriate controls may also be in place to validate the
398 results. This Class also includes those IVD medical devices that present a low

399 public health risk because they detect infectious agents that are not easily
400 propagated in a population.

401

402 **Examples:** Blood gases, *H. pylori* and physiological markers such as
403 hormones, vitamins, enzymes, metabolic markers, specific IgE assays and
404 celiac disease markers.

405

406 **RULE 7:** IVD medical devices that are controls without a quantitative or
407 qualitative assigned value will be classified as Class B.

408

409 **Rationale:** For such controls, the user, not the product owner, assigns the
410 qualitative or quantitative value.

411

412

413 **R2** ► Decision trees illustrating how these rules may be used to classify specific
414 medical devices are shown in Appendix A. ◄

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429


430 **R3** ►

431 **APPENDIX A**

432 The diagrams that follow are for **illustrative purposes only** and the
433 determination of risk class for a particular medical device should be made
434 through reference to the rules and **not solely through decision trees**. Where
435 a medical device has characteristics that place it into more than one risk class,
436 the final risk classification should be based on the **highest** risk class applicable.

GUIDANCE FOR INDUSTRY CONSULTATION


In vitro Diagnostic Devices (1 of 3)



437


438

In vitro Diagnostic Devices (2 of 3)



439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451

In vitro Diagnostic Devices (3 of 3)



452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466

▲ R3

GUIDANCE FOR INDUSTRY CONSULTATION

END OF DOCUMENT

GUIDANCE FOR INDUSTRY CONSULTATION